XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Note 3 - Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Revenues $ 50,645 $ 50,453
Consumables [Member] | Transferred at Point in Time [Member]    
Revenues 27,471 28,277
Hardware and Software [Member] | Transferred at Point in Time [Member]    
Revenues 13,277 12,314
Service [Member] | Transferred at Point in Time [Member]    
Revenues 9,897 9,862
Operating Segments [Member] | Sterilization and Disinfection Control [Member]    
Revenues [1] 15,927 14,774
Operating Segments [Member] | Clinical Genomics [Member]    
Revenues [1] 13,369 14,505
Operating Segments [Member] | Biopharmaceutical Development [Member]    
Revenues [1] 9,889 10,967
Operating Segments [Member] | Calibration Solutions [Member]    
Revenues [1],[2] 11,460 10,207
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]    
Revenues 13,707 12,228
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]    
Revenues 8,769 11,531
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]    
Revenues 4,486 3,664
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]    
Revenues 509 854
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]    
Revenues 81 306
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]    
Revenues 3,427 1,491
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]    
Revenues 2,691 4,824
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]    
Revenues [2] 7,078 5,693
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]    
Revenues 2,139 2,240
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]    
Revenues 1,173 1,483
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]    
Revenues 2,712 2,479
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]    
Revenues [2] $ 3,873 $ 3,660
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021.